GlassScriptPhysician profile
Natalie Asbach
NPI 1558778290
$3,621.21
in general payments reported to CMS, 2019-2025
24 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,082 · 2022: $1,250 · 2023: $765 · 2024: $225 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,289.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $657.70 | 2021-2023 | Dupixent |
| Glaxosmithkline, LLC. | $538.12 | 2021-2023 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $451.66 | 2021-2023 | Fasenra, Tezspire |
| Axsome Therapeutics, INC. | $363.76 | 2023-2025 | Auvelity |
| Pfizer INC. | $295.75 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $147.64 | 2025 | |
| Alexion Pharmaceuticals, INC. | $124.99 | 2024 | |
| Abbvie INC. | $121.83 | 2021 | |
| Genzyme Corporation | $118.64 | 2021-2023 | |
| Kaleo, INC. | $109.02 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.13 | 2021-2022 | |
| Optinose US, INC. | $102.07 | 2021-2022 | |
| Amgen INC. | $94.13 | 2022-2023 | Tezspire |
| Csl Behring | $91.42 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.42 | 2021-2023 | Spiriva Respimat |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $48.35 | 2021 | |
| Incyte Corporation | $44.28 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $26.49 | 2021 | |
| Alk-Abello, INC | $22.89 | 2023 | Odactra, Ragwitek, Grastek |
| Leo Pharma INC. | $22.08 | 2022 | |
| Horizon Therapeutics Plc | $19.79 | 2023 | Actimmune |
| Grifols USA, LLC | $18.29 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.34 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Asbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.